NZ start-up's ginger-based rheumatoid arthritis therapy in clinical trials

NZ start-up's ginger-based rheumatoid arthritis therapy in clinical trials
Evithé Biotechnology founder Cynthia Hunefeld. (Image: Supplied)
Greg Hurrell
A New Zealand start-up is carrying out phase one clinical trials of its rheumatoid arthritis therapy based on the ginger plant.Evithé Biotechnology is a spinout company from Victoria University developing botanical and multi-target pharmaceutical prescription drugs from ginger rhizomes.Beyond rheumatoid arthritis, the company has a pipeline of botanical and pharmaceutical prescription drugs that could get to the root of other inflammatory disorders such as Alzheimer’s disease and sepsis.It hopes to have its first therapies on the m...

More Editor's Picks

Cash or invest? What Allied Farmers could do with $7m
Markets Small Cap Wrap

Cash or invest? What Allied Farmers could do with $7m

Plus, Promisia's insightful guidance, numerous AGMs, and more.

CEOs discover AI not a productivity magic bullet
Editor's Picks Artificial Intelligence

CEOs discover AI not a productivity magic bullet

Why are some businesses struggling to squeeze out productivity gains from AI?

Dileepa Fonseka 23 Oct 2025
FNZ case adds plaintiffs in latest legal twist
Finance

FNZ case adds plaintiffs in latest legal twist

Employee shareholders at FNZ are using a second entity.

Victoria Young 22 Oct 2025
Meridian thinking big after Crown's offer to co-invest
Markets

Meridian thinking big after Crown's offer to co-invest

Govt pledge the biggest change to investment settings since listing in 2013.

Ian Llewellyn 21 Oct 2025